Therefore, NLRP3 inflammasome inhibitors, a new type of anti‐inflammatory drug candidate that is different from the directly blocking IL‐1β, promise to alleviate arthritis symptoms and limit gout flare. The gene discussed is NLRP3; the disease is arthritic joint disease.